80/100 A · Low risk
No major risk flags in the public sources we cover Indicative TraceComp estimate from public sources — an automated indicator, not a credit decision, a completed due-diligence check, or a guarantee. Verify against the official register.

ℹ️ No matches surfaced in the limited public sources we cover (sanctions, screening, insolvency, control). This is an automated indicator — not an exhaustive check, a credit decision, or a guarantee, and absence of a match does not mean none exists. Verify against the official register.

Think this is wrong? This is an automated estimate — request a human review or correction.

BIOCODEX

Active Simplified joint-stock company (SAS) Pharmaceuticals Active for 46 years

Simplified joint-stock company (SAS) · RC 562064600 · Active since 1980

A

Overview

BIOCODEX is a simplified joint-stock company (sas) registered in France, since 1980. The company operates in the pharmaceuticals sector. Its TraceComp score of 80 (A) indicates solid fundamentals and low apparent risk. With 46 years of operations, the company has an established track record in its market.

Company Information

Registration Number
562064600
Legal Form
Simplified joint-stock company (SAS)
Registered
1980-01-01

Public Contracts Won

Awarded 39 public-sector contracts totalling EUR 753,501,539 (DECP).

Which public buyers, contract titles, values and award dates.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Research Output

Active research organization. 171 publications · 16,407 citations · h-index 82 in the global scholarly record (OpenAlex — 82.9M papers). Top fields by publication volume: Medicine (58%) · Neuroscience (20%) · Biochemistry, Genetics and Molecular Biology (12%).

See full research profile — top researchers & publications →

Source: OpenAlex (CC0). Objective publication & citation counts.

Patent Portfolio

Active patent holder. 15 patents · 14 active · 15 granted in the USPTO/EPO record.

See full patent portfolio — most-cited inventions & inventors →

Source: USPTO / EPO open patent data. Objective bibliographic counts.

Corporate Group & Ownership

Parent entities from the GLEIF global ownership graph (LEI Level 2).

RelationshipParent entityCountry
Direct parent PHARCOR FR
Ultimate parent PHARCOR FR

Risk Signals

No adverse legal events have been recorded for this company.

  • No financial filings on record — score derives from registry signals and sector context

Data Sources & Freshness

Data sourced from: bulk register.